Images List Premium Download Classic

Psychiatric

Psychiatric-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive ...
Neurodyn Life Sciences Inc.
January 11, 2018 - N°20180008613

A method for the treatment of a neurodegenerative, psychiatric or neurological disease associated with a cholinergic deficit comprising administering gln-1062 or a pharmaceutically acceptable salt thereof by nasal administration to a patient in need thereof.
Compositions and methods for treating anxiety and compulsive behavior
University Of Iowa Research Foundation
January 04, 2018 - N°20180002295

Provided herein is compositions and methods for treating anxiety, obsession and/or pathologically compulsive behavior associated with various neuropsychiatric diseases.
Aesthetic method of biological structure treatment by magnetic field
Btl Holdings Limited
January 04, 2018 - N°20180001107

Methods and devices producing time varying magnetic field treats a patient. The device contains a coil made of insulated wires, an energy storage device, an energy source and a switch. The coil is flexibly attached in a case. The device has at least one blower for cooling the coil. The methods and devices can be used in for example in ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
Neurovance, Inc.
January 04, 2018 - N°20180000777

The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3. 1. 0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (cns) disorders, including depression and anxiety.
Positive allosteric modulators of the muscarinic acetylcholine receptor m4
Vanderbilt University
December 28, 2017 - N°20170369505

Disclosed herein are tricyclic compounds, including pyrimido[4′,5′:4,5]thieno[2,3-c]pyridazine-8-amine, pyrido[3′,2′:4,5]thieno[3,2-d]pyrimidine-4-amine, pyrazino[2′,3′:4,5]thieno[3,2-d]pyrimidin-4-amine, pyrido[3′,2′:4,5]furo[3, 2-d]pyrimidin-4-amine, and pyrimido[4′,5′:4,5]furo[2,3-c]pyridazin-8-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor m4 (machr m4). Also ...
5,5-bicyclic oxazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
December 28, 2017 - N°20170368035

The present invention is directed to 5,5-bicyclic oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pyrrolidine orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 30, 2017 - N°20170342052

The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention ...
Magnetic field stimulation
The Mclean Hospital Corporation
November 30, 2017 - N°20170340894

A magnetic coil system featuring a multi-layer structure, a spherical shape, or both allows for efficient generation of a gradient magnetic field that induces an electric field in air in a region proximate to the coil. By subjecting at least a portion of a person's brain to the induced electric field various psychiatric disorders can be treated.
(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2...
Bristol-myers Squibb Company
November 30, 2017 - N°20170340653

The disclosure generally relates to compounds of formula i, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nr2b nmda receptor and may be useful for the treatment of various disorders of the central nervous system.
1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment of prevention of neurological and ...
Bristol-myers Squibb Company
November 23, 2017 - N°20170333426

Wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mglur2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mglur2 subtype of metabotropic receptors is involved. The ...
Piperidine isoxazole and isothiazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 16, 2017 - N°20170327490

The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these ...
Methods for treating psychiatric disorders
Merck Sharp & Dohme Corp.
November 16, 2017 - N°20170326356

Methods for treating subjects afflicted with a psychiatric disorders [e. G., autism spectrum disorder (asd), schizophrenia, and/or depression] are described herein. More particularly, the present invention relates to a method for treating a subject afflicted with or at risk for developing a psychiatric disorder (e. G., asd, of which autism is a particular example) that calls for selecting a ...
Composition and method for treatment of neuropsychiatric disorders
Duke University
November 16, 2017 - N°20170326127

The present invention relates to a composition and method for combinative therapy, capable of temporarily regulating inherent dysfunctional neural processes and reducing symptoms and/or signs of neuropsychiatric disorders including, but not limited to, psychostimulant use disorder (pud) and other substance-related additive disorders, post-traumatic stress disorder (ptsd) and other trauma- and stress-related disorders, and levodopa-induced dyskinesia (lid) and other types ...
Psychiatric Patent Pack
Download 117+ patent application PDFs
Psychiatric Patent Applications
Download 117+ Psychiatric-related PDFs
For professional research & prior art discovery
inventor
  • 117+ full patent PDF documents of Psychiatric-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Bridged diazepane orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320876

The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320874

The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Oxazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320865

The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The ...
Amidoethyl azole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170320856

The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present ...
Pyrazole, triazole and tetrazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 09, 2017 - N°20170319560

The present invention is directed to pyrazole, triazole and tetrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole, triazole, and tetrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to ...
Piperidine oxadiazole and thiadiazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 02, 2017 - N°20170313693

The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these ...
Pyrazole orexin receptor antagonists
Merck Sharp & Dohme Corp.
November 02, 2017 - N°20170313684

The present invention is directed to pyrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The ...
Xenon and/or argon treatment as an adjunct to psychotherapy for psychiatric disorders
Merck Sharp & Dohme Corp.
November 02, 2017 - N°20170312308

The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (ptsd) in subjects, e. G., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat ...
Loading